Company / Working Capital
SUTRO BIOPHARMA, INC. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$75.8M
FY2025
5-year range
$75.8M / $327.8M
FY2021-FY2025
Trend
-64.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 8 years, ranging from $76M in FY2025 to $349M in FY2020.
Based on SEC 10-K filings.
$76M in FY2025 with a 5-year CAGR of -26.3%.
Declined from $328M to $76M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -35.8%
- 5-Year CAGR
- -26.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -26.3%, indicating a declining trend.
- In FY2025, working capital decreased 64.1% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $75.8M | -64.1% |
| FY2024 | $211.4M | -35.5% |
| FY2023 | $327.8M | +14.4% |
| FY2022 | $286.6M | +62.1% |
| FY2021 | $176.8M | -49.3% |
| FY2020 | $348.6M | +264.6% |
| FY2019 | $95.6M | -44.9% |
| FY2018 | $173.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026